Intellia Therapeutics, Inc.
NTLA
•Stock Analysis$24.75
+0.00 (+0.00%)• Live
Intellia Therapeutics, Inc. Analysis Dashboard - Stock Analysis and Financial Metrics
Historical Prices
for Intellia Therapeutics, Inc.
Key Financial Metrics
for Intellia Therapeutics, Inc.
P/E Ratio
-1.65
Revenue Growth
+59.55%
EPS Growth
+3.14%
Market Cap
$0.87B
Dividend Yield
0.00%
Debt/Equity
0.15
ROIC
-59.31%
FCF Yield
-43.96%
View additional metrics
Valuation
P/B Ratio1.11
EV/Sales18.86
Financial Health
Current Ratio4.90
Return on Assets-53.33%
Analyst Recommendations
for Intellia Therapeutics, Inc.
36 analysts
Consensus: Buy
About
for Intellia Therapeutics, Inc.
Company Details
for Intellia Therapeutics, Inc.
Sector
Healthcare
Industry
Biotechnology
CEO
John M. Leonard
Employees
403
Market Cap
2.66B
Exchange
NASDAQ Global Market
IPO Date
May 6, 2016
Website
www.intelliatx.comCIK
0001652130
ISIN
US45826J1051
CUSIP
45826J105
Country
US
Balance Sheet
for Intellia Therapeutics, Inc.
Cash Flow Statement
for Intellia Therapeutics, Inc.
Income Statement
for Intellia Therapeutics, Inc.
News
No news available at the moment.